Abciximab is more effective than tirofiban at 30 days after PCI

In the TARGET trial of 4809 patients undergoing stenting, the primary end point (composite of death, nonfatal myocardial infarction, or urgent target vessel revascularization at 30 days) was lower with abciximab (6 versus 7.6 percent for tirofiban, hazard ratio 1.26). The benefit of abciximab was limited to patients with an acute coronary syndrome.